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Abstract 
The biocompatibility and body distribution of PEGylated polyamine nanogels (composed of 
chemically cross-linked poly[2-N,N-(diethylamino)ethyl methacrylate] (PEAMA) gel cores surrounded 
by poly(ethylene glycol) (PEG) chains were investigated to evaluate their feasibility as drug 
nanocarriers for systemic administration.  PEGylated nanogels with different cross-linking densities (1, 
2, and 5 mol%) were prepared to evaluate their biocompatibilities by in vitro cytotoxicity assay, 
hemolysis assay, and in vivo acute toxicity.  The toxic effect of the PEGylated nanogels derived from 
polyamine gel cores was significantly reduced when the cross-linking density was increased, and those 
with a cross-linking density of 5 mol% showed remarkably high median lethal dose (LD50) values >200 
mg/kg, despite the abundance of amino groups in the core.  One hour after intravenous (i.v.) injection, 
the PEGylated nanogels were found to have been eliminated from systemic circulation, and less than 1% 
of the injected dose (I.D.) remained in the bloodstream.  To improve the blood circulation time by 
increasing the surface PEG density of the PEGylated nanogels, post-PEGylation of the PEGylated 
nanogels (through the Menschutkin reaction between the tertiary amines of the PEAMA gel core and 
bromobenzyl-terminated short PEG) was carried out. The biodistribution study of these post-PEGylated 
nanogels revealed that the blood circulation time of the nanogels was definitely prolonged as the PEG 
content was increased.  Therefore, the precise design of PEGylated nanogels, with increased cross-
linking densities in their polyamine gel cores and increased surface PEG densities, seems promising for 
systemic applications. 
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Introduction 
Drug delivery systems (DDSs) have attracted much attention in the field of cancer chemotherapy 
because of their capability for improving quality of life (QOL) by reducing the severity of the side 
effects of drugs while increasing their therapeutic efficacy.  In this regard, precisely constructed drug 
nanocarriers, including polymeric micelles, stealth liposomes, and other nanoparticles, have been 
developed to increase accumulation in the target tissue and release the encapsulated drugs there [1-3].  
The surface modification of these drug carriers with poly(ethylene glycol) chains (PEGylation) 
represents an essential strategy for reducing nonspecific interactions with serum proteins and 
endotheliums in the blood stream, as well as avoiding recognition by immune systems such as the 
reticuloendothelial system (RES) [4-6].  Thus, stabilized nanocarriers tend to show long blood 
circulation times and facilitate accumulation in the tumor tissue through the effects of enhanced 
permeability and retention (EPR) [7].  In addition, external-stimuli-sensitive smart drug carriers that can 
release encapsulated drugs selectively in response to specific environments such as tumor extracellular 
acidic pH and enzymes have been developed to enhance the therapeutic efficacy in the targeted tissue 
[8-10].  Representative nanocarriers such as polymeric micelles and liposomes are prepared through the 
self-assembly of amphiphilic molecules in aqueous media [11, 12]. Pharmacokinetics of nanoparticles 
has been investigated mainly by labeling with fluorescent dyes or radionuclides of these amphiphiles. 
However, because a part of self-assembled nanocarriers may disintegrate during circulation in vivo, it is 
not easy to determine precise pharmacokinetics of intact nanoparticle itself. From the view point of 
pharmacokinetics study of nanoparticles themselves, nanoparticle without disintegration character might 
need to be further investigated.  
We have reported core-shell-type PEGylated nanogels composed of chemically cross-linked 
poly[2-N,N-(diethylamino)ethyl methacrylate] (PEAMA) gel cores surrounded by PEG palisade layers 
[13-18].  Because of their chemically cross-linked polyamine gel core, the PEGylated nanogels show 
high stability against extremely dilute and high-salt conditions, in contrast to self-assembled 
nanocarriers.  Moreover, the nanogels show pH-dependent swelling/deswelling transitions across the 
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pKa of the PEAMA gel core around pH = 7.0 [13,14]; in other words, the nanogels swell in acidic 
conditions due to the increased osmotic pressure in addition to the electrostatic repulsion of the 
protonated PEAMA, and they deswell in alkaline conditions because of the hydrophobic interactions of 
the deprotonated PEAMA. In synchronization with this pH-dependent volume phase transition of such 
PEGylated nanogels, anti-tumor drugs incorporated in the core can be released in response to an acidic 
environment [15].  This polyamine gel core of the nanogels also acts as a reservoir of therapeutic 
molecules, including gold nanoparticles [16] and small interfering RNAs (siRNAs) [17,18], through 
coordination or electrostatic interactions. Although these PEGylated nanogels showed notable 
therapeutic effect under in vitro conditions, their in vivo performance has not yet been demonstrated.  
Therefore, in vivo studies of PEGylated nanogels are needed in order to investigate their possible use in 
clinical applications.  
In this study, the fundamental in vivo behavior of PEGylated nanogels, including their 
biocompatibility and biodistribution after systemic administration, was evaluated.  Biocompatibility 
studies of the PEGylated nanogels, including evaluation of their metabolic activities, hemolytic 
activities, and acute toxicities, were performed to investigate the relationship between the cross-linking 
density of the polyamine gel core and the toxic effect of the nanogel. Biodistribution studies of 
PEGylated nanogels intravenously administered to mice were performed using [125I]-labeled PEGylated 
nanogels. We believe that the optimization of both the “core” and “shell” structures of such nanogels 
might be of significant importance for the development of cancer therapy using PEGylated nanogels as 
well as the development of nanocarriers. 
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2. Materials and Methods 
2-1. Materials 
α-Methoxy-ω-4-vinylbenzyl-PEG (MeO-PEG-VB) and α-acetal-ω-4-vinylbenzyl-PEG (acetal-
PEG-VB) macromonomers were synthesized by ring-opening anionic polymerization of ethylene oxide 
according to previously described methods [16,17].  The number-averaged molecular weight (Mn) and 
polydispersity index (Mw/Mn) of MeO-PEG-VB were 9,500 and 1.05, and those of acetal-PEG-VB were 
10,300 and 1.05, respectively; these were determined by size exclusion chromatography using the PEG 
standard (column: TSKgel G4000HR and TSKgel G3000HR; eluent: THF).  2-(N,N-Diethylamino)ethyl 
methacrylate (EAMA; Wako Pure Chemical Industries, Ltd., Osaka, Japan) and ethylene glycol 
dimethacrylate (EGDMA; Kanto Chemicals Co., Ltd., Tokyo, Japan) were dried over calcium hydride 
and distilled under reduced pressure.  Potassium persulfate (KPS; Kanto Chemicals Co., Ltd.) was 
recrystallized from distilled water and dried under reduced pressure.  Tetrahydrofuran (THF; Kanto 
Chemicals Co., Ltd.) was purified by Glass Contour Solvent dispensing system (Nikko Hansen & Co., 
Ltd., Osaka, Japan).  p-(1-Ethoxyethoxy)styrene (PEES) was kindly provided by Tosoh (Tokyo, Japan) 
and was dried over calcium hydride and distilled under reduced pressure.  Methyl iodide (CH3I), sodium 
hydride (NaH), α,α′-dibromo-p-xylene and 4-[3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate sodium salt (WST-8) (Dojindo, Kumamoto, Japan) were used 
without further purification. 
 
2-2. Synthesis of nanogels by emulsion polymerization 
PEGylated nanogels with different cross-linking densities (1, 2, and 5 mol%) were synthesized by 
emulsion copolymerization by varying the feed EGDMA concentration [13-18].  The typical synthetic 
method for PEGylated nanogels with a cross-linking density of 1 mol% was as follows: acetal-PEG-VB 
(500 mg, 48.5 µmol) and KPS (15.3 mg, 567 µmol) were loaded into a round-bottomed flask equipped 
with a three-way stopcock, and three vacuum and nitrogen purging cycles were carried out.  EGDMA 
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(53.1 µL, 270 µmol) and water (20.3 mL) were then added to the flask.  Since pH of the solution was 
around 8.0, the almost of all monomers were deprotonated under the present conditions.  Emulsion 
polymerization was carried out by adding EAMA (1.09 mL, 5.40 mmol), and the reaction mixture was 
stirred for 24 h at room temperature under a nitrogen atmosphere.  Purification was carried out by 
ultrafiltration (molecular weight cutoff (MWCO) of 200,000) in which methanol was used to remove 
the unreacted starting reagents, and this was followed by ultrafiltration using deionized, distilled water 
to replace the solvent.  The obtained nanogel solution was used as a stock solution, the concentration of 
which was determined by weighing before and after lyophilization. 
 
2-3. Synthesis of PEGylated nanogel bearing vinylphenol moiety and radiolabeling with [125I] 
A PEGylated nanogel bearing vinylphenol moieties, acted as radioisotope (RI) labeling sites, in its 
core (VP-nanogel) was synthesized using the above mentioned emulsion polymerization procedure. 
MeO-PEG-VB (1.0 g, 106 µmol), KPS (30.9 mg, 114 µmol), EGDMA (119  µL, 545 µmol), and EAMA 
(2.17 mL, 10.8 mmol) were reacted in this emulsion polymerization process in the presence p-(1-
ethoxyethoxy)styrene (PEES) (105 µL, 541 µmol), which was used as a precursor for p-vinylphenol.  
The purification was carried out according to the abovementioned procedure.  For the conversion of the 
PEES to phenol groups, the PEES-containing nanogel solution was hydrolyzed by adjusting pH to 2.0 
with 0.1 mol L-1 HCl and stirring for 2 h at room temperature.  After the reaction, the nanogel solution 
was neutralized with 0.1 mol L-1 NaOH, and then subjected to dialysis against distilled water (MWCO = 
3,500) for 24 h to obtain the VP-nanogels.  In this reaction, MeO-PEG-VB was used for the preparation 
of the nanogel instead of acetal-PEG-VB in order to avoid the hydrolysis of the acetal groups and 
undesirable side reactions in the process of PEES hydrolysis. 
Radioiodination of the VP-nanogels was carried out using the chloramine-T method [19, 20]. 
Briefly, Na[125I] solution (2 µL, 148 kBq, Perkin Elmer) and chloramine-T (2.5 mg/mL, 90 µL, 0.9 
µmol) were mixed with the VP-nanogel solution (10 mg/mL, 2 mg). After 10 min of reaction at room 
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temperature, an excess of sodium persulfate (9.5 mg/ml, 200 µL, 8 µmol) was added to stop the reaction, 
and the mixture was passed through a gel filtration column (PD-10 column, GE Healthcare, eluent: 10 
mM phosphate buffer with 150 mM NaCl, pH 7.4) to remove unreacted Na[125I] and the starting 
reagents. Each 500 µL fraction was collected and its radioactivity measured by a γ-counter (ARC-380, 
Aloka, Tokyo, Japan) to confirm the [125I]-labeling of the VP-nanogel.  The specific radioactivity of the 
[125I]-labeled VP-nanogel was determined to be 1120 kcpm/mg.  The obtained [125I]-labeled VP-nanogel 
solutions were diluted with phosphate buffered saline (PBS) to adjust the radioactivity to 1.0 Mcpm/mL, 
and they were used for the in vivo body distribution studies. 
 
2-4. Synthesis of α-methoxy-ω-bromobenzyl-PEG and post-PEGylation of nanogel 
The installation of the bromobenzyl moiety at the ω-end of PEG was carried out with α,α′-
dibromo-p-xylene according to a previously described method [21].  Briefly, MeO-PEG-OH (Mn = 480, 
Mw/Mn = 1.07, 480 mg, 1.0 mmol) was dissolved in THF (60 mL), and this was followed by successive 
addition of NaH (36 mg, 1.5 mmol), NaI (150 mg, 1.0 mmol), and α,α′-dibromo-p-xylene (2.6 g, 10 
mmol). The reaction mixture was stirred for 96 h at room temperature under light shielding.  After 
passing through a plug of celite, the low-molecular-weight starting reagents were removed by silica gel 
column chromatography.  The purified polymer was dissolved in 1,4-dioxane and then lyophilized to 
obtain α-methoxy-ω-bromobenzyl-PEG (MeO-PEG-Bz-Br) as an oil (98.2% yield).  The structure of 
the obtained MeO-PEG-Bz-Br was determined by 1H NMR (Avance 500 MHz NMR, Bruker, 
Supporting information, Figure S1). 
The quaternization reaction of the tertiary amino groups in the core of the VP-nanogel was 
performed according to a previously described method with slight modifications [18, 22].  Aqueous 
solutions of VP-nanogels (2 mL, 50 mg/mL) were diluted fourfold with acetonitrile, and subsequently, 
MeO-PEG-Bz-Br was added (0.89 mmol or 8.9 mmol: 0.5 or 5.0 molar equivalents against amino 
groups).  The mixture was reacted for 72 h at room temperature.  After the reaction, the obtained 
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nanogel solutions were purified by ultrafiltration (MWCO = 200,000) as described above. Model 
quaternized polyamine nanogel (QNG) was synthesized under the similar conditions to that of post-
PEGylated nanogel using methyl iodide instead of MeO-PEG-Bz-Br. Briefly, VP-nanogels solution 
(100 mg, 1.78 mmol of tertiary amino groups) was dialyzed against 500 mL of methanol (dialysate was 
changed 4 times after 3 h, 6 h, 12 h and 24 h) to convert the solvent. After the solvent was completely 
converted to methanol, CH3I was added to the solution (5.33 mmol: 3 molar equivalents against amino 
groups). The mixture was reacted for 48 h at room temperature. After the reaction, the obtained QNG 
solutions were purified by ultrafiltration (MWCO = 200,000), the procedure of which was similar to that 
of post-PEGylated nanogels.   The extent of substitution (ES) of EAMA with MeO-PEG-Bz-Br or CH3I 
was determined by quantifying the residual EAMA by potentiometric titration using an automatic 
titrator (Mettler DL-25, Mettler-Toledo, Greifensee, Switzerland), according to a previously described 
method [22]. 
 
2-5. Size and ζ-potential measurements 
Nanogels showed phase transition at around pH = 7, reflecting the pKa of PEAMA in physiological 
condition (pKa = 7.1) [18], and more than 95% of amino group in the core were protonated at pH = 5.5 
[18]. In addition, pH in lysosome is reported to become less than 6.0 [15]. Thus, we have chosen pH = 
5.5 to characterize nanogel under acidic conditions. The size of the nanogel was evaluated by dynamic 
light scattering (DLS) on a Zetasizer Nano ZS (Malvern Instruments, Ltd., U.K.) equipped with a 4 mW 
He-Ne ion laser (λ = 633 nm).  The DLS measurements were carried out at 37.0 °C at a detection angle 
of 173° in 10 mM phosphate buffer solution containing 150 mM NaCl at pH 5.5 or 7.4.  The obtained 
correlation functions were analyzed by the cumulant method to determine the hydrodynamic diameters 
and polydispersity indices (µ2/Γ2). 
  Measurements of the ζ-potential of the nanogels were performed on a Zetasizer Nano ZS. The 
measurements were carried out at 37.0 °C in 10 mM phosphate buffer solution at pH = 5.5 or 7.4. 
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2-6. Cytotoxicity studies 
Colon-26 cells, derived from murine rectum carcinoma, were seeded at a density of 1×104 
cells/well in a 96-well plate and incubated overnight at 37 °C in a 5% CO2 humidified atmosphere.  The 
nanogel was added at a concentration in the range 0.1 to 1.0 mg/mL, and the cells were incubated at 
37 °C for 24 h.  Then, 10 µL of WST-8 reagent [23] was added to each well, and the cells were 
incubated for a further 1 h at 37 °C. The absorbance at 450 nm of the formazan produced by living cells 
was measured using a microplate reader (Varioskan; Thermo Electron Co., Waltham, MA).  The cell 
viability was calculated relative to the untreated cells. 
 
2-7. Hemolysis test 
Whole blood was collected from ICR mice (Charles River, Yokohama, Japan), and was centrifuged 
at 3000 rpm for 5 min to isolate the red blood cells (RBCs), which were then washed three times with 
cold PBS. The nanogel solutions (975 µL) were added to RBC solution (25 µL; 4×108 cells/mL), and 
incubated for 60 min at 37 °C with shaking at 300 rpm.  After the incubation, intact RBCs were 
separated by centrifugation (3000 rpm for 5 min) and 100 µL of supernatant was collected.  The amount 
of hemoglobin release was determined by reading the absorbance at 540 nm on a Varioskan microplate 
reader.  To determine 100% hemolysis, RBCs were lysed with 1% Triton-X, and the hemolytic activity 
of the nanogels was calculated relative to the Triton-X. Less than 10% hemolysis was regarded as a 
nontoxic level in our experiments [24]. 
 
2-8. Median lethal dose (LD50) in acute toxicity study  
For the animal experiments, all procedures and animal care were approved by the Committee on 
the Ethics of Animal Experimentation of the University of Tsukuba and were conducted according to 
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the Guidelines for Animal Experimentation of the University of Tsukuba.  Four-week-old male ICR 
mice (Crlj: CD1 mice) were purchased from Charles River, Japan. The LD50 values of the nanogels 
were determined by intravenous injection of the nanogel solutions into the ICR mice.  The nanogel 
doses were elevated to 20, 50, 100, and 200 mg/kg of the mouse body weight.  The experiments were 
carried out on 5–8 mice for each group. 
 
2-9. Blood circulation and tissue distribution of nanogel 
The [125I]-labeled nanogel (200 µL, 200 kcpm) was injected into the tail veins of four-week-old 
ICR mice.  After a prescribed time period, the mice were anesthetized with diethyl ether.  Blood was 
then collected via cardiac puncture, and this was followed by perfusion with 10 mL of saline.  
Afterward, the major organs (heart, lung, liver, kidney, and spleen) were collected and their 
radioactivities were measured using a γ-counter (ARC380).  The data were normalized with the 
radioactivity of the injected dose. 
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3. Results and Discussion 
3-1. Synthesis and characterization of PEGylated nanogels with different cross-linking densities 
The biocompatibility of drug carriers is a major concern for clinical applications.  Therefore, the 
toxic effects of the PEGylated nanogels were evaluated in terms of their cytotoxicity, hemolytic activity, 
and in vivo acute toxicity.  Previously, it was revealed that the cytotoxicity of PEGylated nanogels is 
largely dependent on the cross-linking density of the polyamine core, and the PEGylated nanogel with a 
cross-linking density of 1 mol% showed lower cytotoxicity than that with 0.1 mol% cross-linking 
density [25].  In this study, the cross-linking densities of the PEGylated nanogels were varied from 1 to 
5 mol%, and their cytotoxicities were evaluated. The physicochemical characteristics of the pH-
sensitive PEGylated nanogels with different cross-linking densities are summarized in Table 1.  
Although the size of each nanogel at a pH of 7.4 is comparable regardless of the cross-linking density, 
the swelling ratios of the nanogels (volume ratio at pH values of 5.5 to 7.4) decreased with increasing 
cross-linking density of the polyamine gel core due to the restriction of the swelling by the highly cross-
linked structure.  The ζ-potential of all nanogels showed a similar tendency, decreasing with increasing 
cross-linking density of the polyamine gel core at a pH of 5.5, but having a value of almost zero at pH = 
7.4.  This result indicates that the dangling polyamine chains from the core network were exposed to the 
outer shell, whereas at high cross-linking densities they were confined to the core.  Thus, PEGylated 
nanogels with different cross-linking densities were successfully synthesized. 
 
3-2. Effect of cross-linking density of PEGylated nanogels on in vitro toxicities 
For the evaluation of the cytotoxicity of these nanogels, colon-26 cells were exposed to each 
nanogel for 24 h and their viability was determined by the WST-8 assay, as shown in Figure 1. The 
cytotoxicity of the nanogels was remarkably reduced by increasing their cross-linking densities. The 
value of 50% of inhibitory concentration (IC50) values of nanogels with cross-linking densities of 1, 2, 
and 5 mol% were determined to be 12, 190, and >1000 µg/mL, respectively.  For the further evaluation 
of the toxicity of the nanogels, their hemolytic activities were evaluated after incubation with RBCs for 
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1 h (Figure 2).  Similar to the results of the cytotoxicity assay, 10% of hemolytic concentration (HC10) 
values of the nanogels with cross-linking densities of 1, 2, and 5 mol% were determined to be 10, 230, 
and 700 µg/mL, respectively. Generally, most cationic polymers, including poly(ethylenimine) (PEI) 
and poly(L-lysin) (PLL), showed high toxicities; this is brought about by the electrostatic interactions 
between the positively charged polycations and the negatively charged cellular membrane, and the 
consequent membrane disruption [26].  Thus, these results suggest that highly cross-linked nanogels 
show negligible contact with cells or RBCs because the high level of cross-linking in the gel structure 
decreases the exposure of the polyamines, as stated above.  It is noteworthy, that the PEGylated 
nanogels with a cross-linking density of 5 mol% showed negligible toxicities despite the abundance of 
amino groups in the core maintaining their pH sensitivity. 
In order to validate the lowered toxicity of these highly cross-linked nanogels under in vivo 
conditions, we evaluated their acute toxicities via i.v. administration in mice.  Figure 3 shows the 
survival rate of mice after i.v. administration of each nanogel for different injected doses.  The median 
lethal doses (LD50) of nanogels with cross-linking densities of 1, 2, and 5 mol% were determined to be 
<20, 92, and >200 mg/kg, respectively, meaning that the acute toxicities of the nanogels against mice 
were significantly reduced by increasing their cross-linking densities.  These results are well correlated 
with the tendencies found for the in vitro cytotoxicity and hemolytic activity.  It should be noted that the 
PEGylated nanogels with a cross-linking density of 5 mol% showed significantly higher LD50 values 
than linear PEI (5 mg/kg) and PLL (<30 mg/kg) [27,28].  Thus, increasing the cross-linking densities of 
the polyamine gel cores of these nanogels is a rational method for reducing both the in vitro and in vivo 
toxicities of the amines. 
 
3-3. [125I]-labeling of PEGylated nanogels and biodistribution studies 
Since nanogels with low cross-linking density (1 mol% and 2 mol%) showed fairly high acute 
toxicity in vivo within several hours after i.v. administration (Figure 3), these samples were excluded 
from biodistribution study. Thus pharmacokinetics study was performed only nanogels with a cross-
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linking density of 5 mol%.  To verify the biodistrubution of systemically administered PEGylated 
nanogels, we labeled them with radioisotopes.  For the biodistribution study, the nanogel containing the 
p-vinylphenol moiety (VP-nanogel) with a cross-linking density of 5 mol% was newly synthesized for 
the [125I]-labeling, as shown in Scheme 1; PEES was used as a precursor for vinylphenol to avoid the 
side reaction between the radical species and vinylphenol.  After the deprotection of PEES under acidic 
conditions, the VP-nanogel was successfully obtained without any side reaction.  Note that the 
installation of 5 mol% vinylphenol in the core of the nanogel did not affect the size, swelling ratio, or 
cytotoxicity (data not shown). 
Radiolabeling of the VP-nanogel with [125I] was carried out using the chloramine-T method [19,20], 
and [125I]-labeling was confirmed by size exclusion chromatography on a PD-10 column (Supporting 
information, Figure S2). When the PEGylated nanogels containing vinylphenol moieties were reacted 
with Na[125I] and chloramine-T, almost all the [125I] was labeled to the nanogels, whereas the PEGylated 
nanogels without vinylphenol could not be labeled with [125I] through this procedure.  Additionally, 
PEGylated nanogels containing non-deprotected PEES moieties could not be labeled with [125I] (data 
not shown), indicating that the nanogels were selectively labeled with [125I] at the vinylphenol moieties 
of their cores. 
The [125I]-labeled nanogels were injected intravenously in mice at 200 kcpm/mouse, and the 
concentration of the VP-nanogel in systemic circulation and its major organs (heart, lung, liver, spleen 
and kidney) were evaluated 5 min, 1 h, and 3 h i.v. injection.  One hour after i.v. injection, the 
concentration of VP-nanogel in the blood was found to be below 1% I.D., and approximately 70% of the 
VP-nanogel was accumulated in the liver and spleen (Figure 4). The 5 mol% cross-linked nanogel 
showed a ζ-potential of about zero and fairly low cytotoxicity, as well as low in vitro hemolytic 
concentration as stated above. In the in vivo experiments, almost all the nanogel was eliminated from the 
blood stream within 1 h.   This fact means that the recognition level of exogenous synthetic materials 
under in vivo condition might be extremely sensitive compared to that in vitro conditions, and only the 
surface charge shielding and/or hemolytic concentration is not adequate for systemic applications.  
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Although the ζ-potential of the PEGylated nanogel with 5 mol% cross-linking was close to zero, the 
living body recognized the internal surface charge of the nanogel.  Indeed, PEGylated polyion 
complexes between PEG-PEI copolymer and siRNA shows short blood circulation time, presumably 
due to the exogenous recognition arising from their internal positive charge [29, 30].  In order to 
improve the stealth character of nanogels, an uncompromised surface design must be achieved.  In this 
biodistribution study, PEG macromonomers with relatively high molecular weight (Mn = 9,500) were 
employed for the nanogel synthesis. However, intravenously administered nanogels were rapidly 
eliminated from systemic circulation, as shown in Figure 4.  We have previously reported the 
construction of mixed-PEG brush surface which is coimmobilization of long and short PEG chains with 
different molecular weight to increase PEG density and improve non-fouling character of the substrate 
surface [31, 32]. In order to improve the surface character, the installation of a short PEG brush on the 
PEGylated nanogels was examined.  
 
3-4. Biodistribution studies of post-PEGylated nanogels. 
We have already confirmed that a density of PEG chain tethered on nanogel surface did not change 
regardless of the reaction condition due to the steric repulsion of PEG chain.  The average PEG chain 
density was ca. 0.03 chain / nm2, which is not enough high for anti-biofouling character [33]. From our 
basic investigation on density of PEG tethered chain on non-specific adsorption of proteins, at least 0.4 
chains/nm2 is required for flat surface [34]. Rounded particle surface requires much more PEG chain 
density. To increase the PEG density of the nanogels, we carried out post-PEGylation through the 
Menschutkin reaction between the EAMA moieties in the core of the nanogel and the bromobenzyl-
terminated PEG, as shown in Scheme 2.  This post-PEGylation technique may also be applied to new 
methodology for ligand installation using bifunctional PEG.  As a control, quaternized polyamine 
nanogel (QNG) was synthesized through the same procedure, because the EAMA moieties are 
converted into the quaternized ammonium form by the Menschutkin reaction.  In this reaction, short 
MeO-PEG-Bz-Br (Mn = 500) was employed to construct a mix-PEG tethered chain structure.  The 
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amount of modified PEG was determined by quantifying the residual EAMA by potentiometric titration.  
The extent of substitution (ES) of EAMA with PEG-Bz-Br at feed [PEG-Bz-Br]/[N] ratios of 0.5 and 
5.0 was 64% and 92%, respectively (Table 2).  The obtained post-PEGylated nanogels (PNGs) are 
abbreviated as PNG(64) and PNG(92), respectively, based on their ES of short PEG; PNG(0), PNG(64) 
and PNG(92) contains 0.9 mol%, 37.1 mol% and 45.8 mol% of total PEG chains (PEG macromonomer 
+ post-modified short PEG), respectively. After [125I]-labeling, the blood circulation time and body 
disposition of systemically administered PNG were investigated, and it was found that the insertion of 
shorter PEG chains extended the blood circulation time of the nanogels (Figure 5).  The % I.D. of 
PNG(64) and PNG(92) 1 h after i.v. administration in the blood was 2% I.D. and 7% I.D., respectively, 
clearly showing that the blood circulation time of the nanogels was prolonged as the ES of the 
underlayered PEG increased. There are several reports on prolonged blood circulation of nanoparticles 
such as PEGylated liposomes and polymer micelles. For example, block copolymer micelle composed 
of peptide-PEG-b-poly(D,L-lactide) showed fairly long circulating character (20% of injected dose 
retained in blood stream after 24 h) [35]. In the present nanogel system, however, post-PEGylation was 
carried out via Menschutkin reaction, which introduced fixed cationic charge in the core. In spite of the 
increase in fixed positive charge, the blood circulation of PNG(94) increased to 7% I.D., indicating 
strong entropically shielding effect of PEG layer owing to the increase in its density by the post-
PEGylation reaction. To further confirm the contribution of this underlayered PEG, the blood 
circulation time of QNG was investigated.  However, the quaternized amines in the core of the nanogel 
did not affect the blood circulation time, with QNG showing blood circulation similar to the case of 
unmodified nanogels (Figure 5a).  To verify the prolonged blood circulation time of the nanogels, their 
accumulation in major tissues was investigated.  The body distributions of PNG(64) and PNG(92) are 
shown in Figure 5b; the liver accumulation was significantly decreased by the installation of quaternary 
amines, while the lung accumulation was increased as compared to PNG(0).  The lung accumulation of 
QNG was of the same level PNG(64) and PNG(92) (Figure 5).  Therefore, the increased lung 
accumulation observed for systemically administered PNG was presumably due to the effect of the 
 16 
quaternary amine moieties. Although decrease in lung accumulation of PNG(92) is slight compared to 
that of PNG(64), definite difference was observed (p < 0.05), indicating that increase in the PEG chain 
density on particle surface suppresses non-specific entrapment in reticuloendothelial system in lung.  
These biodistribution results suggest that the prolonged blood circulation time observed for PNG was 
mainly because of the increase in surface PEG density with the mix-PEG tethered chain structure, and 
not a result of the contribution of the quaternary amino groups.  In this study, short PEG (Mn = 500) was 
utilized as the underlayer PEG for post-PEGylation.  Despite its prolonged blood circulation, the use of 
PNG is still controversial due to its rapid diffusion throughout the body, especially in major organs such 
as liver, spleen, and lung. The rapid diffusion of drug carriers in these tissues causes the decrease in the 
therapeutic effect on targeted tissue (e.g. tumor tissue), as well as increase the severity of side effects. 
The lung accumulation of PNG might be reduced when longer PEG is employed for further post-
PEGylation. Further investigations are now in progress and will be published elsewhere. 
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Conclusion 
The impact of different cross-linking densities nanogel cores on their toxicity was determined.  
When the cross-linking density of the nanogels was increased, the nanogels showed negligible in vitro 
and in vivo toxicities, despite the abundance of amino groups in the core.  Accordingly, the LD50 values 
of nanogels with a cross-linking density of 5 mol% were greater than 200 mg/kg. The body disposition 
study of PEGylated nanogels revealed that intravenously administered nanogels were rapidly eliminated 
from the blood, even though their size was below 100 nm and ζ-potential measurements showed a 
neutral surface charge.  Thus, the in vitro physicochemical characteristics of PEGylated nanogels seem 
to be insufficient for estimating the in vivo biodistribution.  To improve the blood circulation time, 
surface PEG density of nanogels were further increased by post-PEGylated reaction by Menschutkin 
reaction using bromobenzyl-terminated short PEG.  The blood circulation time of thus synthesized post-
PEGylated nanogels was prolonged as the short PEG content increased. The % I.D. of post-PEGylated 
nanogel, with 92% of the extent of substitution of EAMA moieties in the nanogels with PEG-Bz-Br, 
was about seven times higher than that of nanogels without post-PEGylation. In spite of the increase in 
fixed positive charge by the Menschutkin reaction with short PEG-Bz-Br, the blood circulation of 
PNG(94) increased to 7% I.D., indicating strong entropically shielding effect of PEG layer owing to the 
increase in its density by the post-PEGylation reaction. Thus, PEG chain density on the surface of 
nanoparticle primarily works to improve their blood circulation character. Several other methods to 
increase in PEG shell layer are now in progress in our group and will be published elsewhere. 
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Tables 
Table 1. The sizes and ζ-potentials of PEGylated nanogels with different cross-linking densities 
feed EGDMA 
(mol%) 
size (nm)*1 ζ-potential (mV)*2 
swelling ratio*3 
pH = 5.5 pH = 7.4 pH = 5.5 pH = 7.4 
1 141 97 6.4 0.3 3.2 
2 115 93 3.4 0.03 2.0 
5 116 103 0.6 0.1 1.4 
*1 As determined by DLS in phosphate buffer (10 mM PB, 150 mM NaCl) at 37 °C  
*2 As determined by electrophoretic light scattering in phosphate buffer (10m M PB) at 37 °C  
*3 The swelling ratio of nanogel is defined as the volume ratio at pH = 5.5/pH = 7.4 
 
 
Table 2. Characterization of nanogels reacted with bromobenzyl-terminated short PEG 
feed [MeO-PEG-Bz-
Br]/[EAMA] ratio 
(mol/mol) 
size (nm)*1 ζ-potential (mV)*2 Swelling  
ratio*3 
ES (%)*4 
pH = 5.5 pH = 7.4 pH = 5.5 pH = 7.4 
0 91 73 2.7 0.6 1.9 0 
0.5 104 99 - 0.1 0.1 1.2 64 
5.0 109 108 0.0 0.1 1.0 92 
*1 As determined by DLS in phosphate buffer (10 mM PB, 150 mM NaCl) at 37 °C  
*2 As determined by electrophoretic light scattering in phosphate buffer (PB 10 mM) at 37 °C  
*3 The swelling ratio of nanogel is defined as the volume ratio at pH = 5.5/pH = 7.4 
*4 ES = extent of substitution of EAMA with MeO-PEG-Bz-Br (Mn = 500) determined by 
potentiometric titration 
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Scheme 1. [125I]-labeling of PEGylated nanogel containing vinylphenols by the chloramine-T method 
 
  
Scheme 2. Synthesis of post-PEGylated nanogels by the Menschutkin reaction with bromobenzyl-
terminated short PEG 
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Figure captions  
 
Figure 1. Cytotoxicities of PEGylated nanogels with different cross-linking densities against colon-26 
cells, as determined by the WST-8 assay after 24 h incubation. The plots represent PEGylated nanogels 
with cross-linking densities of 1 mol% (closed squares), 2 mol% (closed triangles), and 5 mol% (open 
circles). The data are expressed as mean ± S.D. (n = 6). 
 
Figure 2. Hemolytic activities of PEGylated nanogels with different cross-linking densities against 1 × 
107 RBCs after 1 h incubation. The plots represent PEGylated nanogels with cross-linking densities of 1 
mol% (closed squares), 2 mol% (closed triangles), and 5 mol% (open circles). The data are expressed as 
mean ± S.D. (n = 3). 
 
Figure 3. Survival rate of ICR mice 24 h after i.v. administration of PEGylated nanogels with different 
cross-linking densities. The plots represent PEGylated nanogels with cross-linking densities of 1 mol% 
(closed squares), 2 mol% (closed triangles), and 5 mol% (open circles). (n = 5–8). 
 
Figure 4. The biodistribution of [125I]-labeled nanogels with a cross-linking density of 5 mol% (a) Time 
course of % I.D. of [125I]-labeled nanogels in the blood after i.v. administration. (b) Body disposition of 
[125I]-labeled nanogels 1 h after i.v. administration. The data are expressed as mean ± S.D. (n = 4). 
 
Figure 5. The difference in biodistribution of post-PEGylated [125I]-labeled nanogels with a cross-
linking density of 5 mol% (a) Time course of % I.D. of [125I]-labeled nanogels with different degrees of 
short PEG substitution and 98% CH3I substitution (QNG) in the blood after i.v. administration. (b) 
Body disposition of [125I]-labeled nanogels with different short PEG and QNG 1 h after i.v. 
administration. The plots and bars represent the PEGylated nanogels with different degrees of PEG-Bz-
Br substitution 0 (black symbols), 64 (cancellous symbols), and 92 mol% (dot symbols) and for a CH3I 
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substitution degree of 98% (diagonal symbols). The data is expressed as mean ± S.D. (n = 4). *p < 0.05 
significantly different from nanogel with ES% = 0 by one-way ANOVA with Student’s t-test. 
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(b) 
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Figure 5 
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(b) 
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Figure S1. 1H-NMR chart of MeO-PEG-Bz-Br in CDCl3. The integration values were follows: Peak a = 
2.95H, b =52H, c = 1.93H, d = 1.94H, e = 1.82H and f = 1.82H. 
 
Figure S2. Size exclusion chromatograms of PEGylated nanogel bearing vinylphenol moieties in the 
core (closed lozenges) and control nanogels without vinylphenol moieties (closed squares) after reaction 
with Na[125I], detected by γ-counter. 
 
